FGFR1 and lung carcinoma: The optimized protocol withPEGylated auristatin yielded doubly substituted peptibodyC19, showingspecific cytotoxicity toward the FGFR1-expressing lung cancer cells,with no effect on cells with low FGFR1 levels.